PE20030641A1 - Composicion nanoparticulada de 2-(r)-(1-(r)-(3,5-bis(trifluorometil)fenil)etoxi)-3-(s)-(4-fluoro)fenil-4-(3-(5-oxo-1h,4h-1,2,4-triazolo)metil morfolina) - Google Patents
Composicion nanoparticulada de 2-(r)-(1-(r)-(3,5-bis(trifluorometil)fenil)etoxi)-3-(s)-(4-fluoro)fenil-4-(3-(5-oxo-1h,4h-1,2,4-triazolo)metil morfolina)Info
- Publication number
- PE20030641A1 PE20030641A1 PE2002001173A PE2002001173A PE20030641A1 PE 20030641 A1 PE20030641 A1 PE 20030641A1 PE 2002001173 A PE2002001173 A PE 2002001173A PE 2002001173 A PE2002001173 A PE 2002001173A PE 20030641 A1 PE20030641 A1 PE 20030641A1
- Authority
- PE
- Peru
- Prior art keywords
- phenyl
- spheres
- trifluorometil
- etoxy
- oxo
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 4
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical class [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 title abstract 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 title 1
- 239000007787 solid Substances 0.000 abstract 2
- CDOUZKKFHVEKRI-UHFFFAOYSA-N 3-bromo-n-[(prop-2-enoylamino)methyl]propanamide Chemical compound BrCCC(=O)NCNC(=O)C=C CDOUZKKFHVEKRI-UHFFFAOYSA-N 0.000 abstract 1
- 208000020401 Depressive disease Diseases 0.000 abstract 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 abstract 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 1
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 abstract 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 abstract 1
- 229920002472 Starch Polymers 0.000 abstract 1
- 206010047700 Vomiting Diseases 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 235000010980 cellulose Nutrition 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 208000015114 central nervous system disease Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229920001577 copolymer Polymers 0.000 abstract 1
- 235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 abstract 1
- 229910052731 fluorine Inorganic materials 0.000 abstract 1
- 239000011737 fluorine Substances 0.000 abstract 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 abstract 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 1
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 1
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 abstract 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 abstract 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 239000003381 stabilizer Substances 0.000 abstract 1
- 239000008107 starch Substances 0.000 abstract 1
- 235000019698 starch Nutrition 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Otolaryngology (AREA)
- Rheumatology (AREA)
- Physics & Mathematics (AREA)
- Nanotechnology (AREA)
- Optics & Photonics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
SE REFIERE A UNA COMPOSICION NANOPARTICULADA QUE COMPRENDE DE 5% A 60% DE UN ANTAGONISTA DEL RECEPTOR DE TAQUICININA TAL COMO 2-(R)-(1-(R)-(3,5-BIS(TRIFLUOROMETIL)FENIL)ETOXI)-3-(S)-(4-FLUORO)FENIL-4-(3-(5-OXO-1H,4H-1,2,4-TRIAZOL)METILMORFOLINA; DE 1% A 20% DE UN ESTABILIZANTE ABSORBIDO EN LA SUPERFICIE DEL COMPUESTO O EN UNA CANTIDAD PARA MANTENER UN PROMEDIO EFECTIVO DE TAMANO DE PARTICULAS MENOR DE 1000nm, TAL COMO CELULOSA HIDROXIPROPILICA, CELULOSA HIDROXIPROPILMETILICA, CELULOSA HIDROXIPROPILICA DE VISCOSIDAD SUPERBAJA, POLIVINILPIRROLIDONA, COPOLIMEROS DE OXIDO DE ETILENO, OXIDO DE PROPILENO, SULFOSUCCINATO DE DIOCTIL SODIO Y SULFATO DE LAURIL SODIO; DE 0% A 50% DE UN AGENTE REDISPENSANTE, DE 0% A 90% DE UN SOPORTE SOLIDO; DE 0% A 5% DE UN LUBRICANTE. LA COMPOSICION SE HA DESECADO POR ASPERSION O REVESTIDO POR ASPERSION SOBRE UN SOPORTE SOLIDO SELECCIONADO A PARTIR DE ESFERAS DE CELULOSA MICROCRISTALINA, ESFERAS DE AZUCAR ALMIDON Y ESFERAS DE LACTOSA. LA COMPOSICION PRESENTA UNA MAYOR BIODISPONIBILIDAD ORAL Y PUEDE SER UTIL PARA EL TRATAMIENTO DE TRASTORNOS DEL SISTEMA NERVIOSO CENTRAL, TRASTORNOS PSIQUIATRICOS, DEPRESION ANSIEDAD, ENFERMEDADES INFLAMATORIAS, EMESIS
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34004001P | 2001-12-10 | 2001-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20030641A1 true PE20030641A1 (es) | 2003-07-23 |
Family
ID=23331619
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2002001173A PE20030641A1 (es) | 2001-12-10 | 2002-12-05 | Composicion nanoparticulada de 2-(r)-(1-(r)-(3,5-bis(trifluorometil)fenil)etoxi)-3-(s)-(4-fluoro)fenil-4-(3-(5-oxo-1h,4h-1,2,4-triazolo)metil morfolina) |
Country Status (38)
| Country | Link |
|---|---|
| US (1) | US8258132B2 (es) |
| EP (1) | EP1455756B2 (es) |
| JP (1) | JP4532114B2 (es) |
| KR (1) | KR20040063991A (es) |
| CN (1) | CN100352443C (es) |
| AR (1) | AR037713A1 (es) |
| AT (1) | ATE400254T1 (es) |
| AU (1) | AU2002360824B8 (es) |
| BR (1) | BRPI0214786B8 (es) |
| CA (1) | CA2469315C (es) |
| CO (1) | CO5590887A2 (es) |
| CY (1) | CY1108354T1 (es) |
| DE (1) | DE60227556D1 (es) |
| DK (1) | DK1455756T4 (es) |
| DO (1) | DOP2002000542A (es) |
| EA (1) | EA007332B1 (es) |
| EC (1) | ECSP045144A (es) |
| ES (1) | ES2307820T5 (es) |
| GE (1) | GEP20063875B (es) |
| HR (1) | HRP20040532B1 (es) |
| HU (1) | HU230736B1 (es) |
| IL (3) | IL162296A0 (es) |
| IS (1) | IS2991B (es) |
| JO (1) | JO3060B1 (es) |
| ME (1) | ME00450B (es) |
| MX (1) | MXPA04005563A (es) |
| MY (1) | MY155911A (es) |
| NO (1) | NO336943B1 (es) |
| NZ (1) | NZ534009A (es) |
| PE (1) | PE20030641A1 (es) |
| PL (1) | PL211243B6 (es) |
| PT (1) | PT1455756E (es) |
| RS (1) | RS52280B (es) |
| SI (1) | SI1455756T2 (es) |
| TW (1) | TWI249403B (es) |
| UA (1) | UA76810C2 (es) |
| WO (1) | WO2003049718A1 (es) |
| ZA (1) | ZA200404012B (es) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1479300B1 (en) * | 2002-02-22 | 2009-10-21 | Ajinomoto Co., Inc. | Amino acid powder and process for producing the same |
| TWI366442B (en) * | 2003-07-30 | 2012-06-21 | Novartis Ag | Palatable ductile chewable veterinary composition |
| US20090004277A1 (en) * | 2004-05-18 | 2009-01-01 | Franchini Miriam K | Nanoparticle dispersion containing lactam compound |
| EP2332524A1 (en) * | 2005-02-15 | 2011-06-15 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
| CA2617211A1 (en) * | 2005-07-29 | 2007-02-08 | Dr. Reddy's Laboratories Ltd. | Amorphous aprepitant coprecipitates |
| KR20120107533A (ko) | 2005-11-28 | 2012-10-02 | 마리누스 파마슈티컬스 | ｇａｎａｘｏｌｏｎｅ 제형, 이의 제조방법 및 용도 |
| US9227958B2 (en) * | 2006-02-03 | 2016-01-05 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
| US20090209541A1 (en) * | 2006-06-16 | 2009-08-20 | Dr. Reddy's Laboratories Ltd. | Aprepitant compositions |
| WO2008026216A2 (en) * | 2006-08-28 | 2008-03-06 | Hetero Drugs Limited | Process for purification of aprepitant |
| WO2008066899A2 (en) * | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
| EP1970057A1 (en) * | 2007-03-13 | 2008-09-17 | Sandoz AG | Process for the preparation of stable pharmaceutical compositions of 2-(R) - (1-(R)-(3, 5- bis (trifluoromethyl) phenyl) ethoxy)-3-(S)-(4-fluoro) phenyl-4-(3-(5-oxo-1H, 4H-1, 2, 4-triazolo) methylmorpholine (aprepitant) |
| US20100151035A1 (en) * | 2007-03-13 | 2010-06-17 | Sandoz Ag | Pharmaceutical compositions of poorly soluble drugs |
| US20110009362A1 (en) * | 2008-02-27 | 2011-01-13 | Dr. Reddy's Laboratories Ltd. | Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof |
| WO2009116081A2 (en) * | 2008-03-03 | 2009-09-24 | Msn Laboratories Limited | An improved process for the preparation of aprepitant |
| JP2012513978A (ja) * | 2008-12-30 | 2012-06-21 | アブディ イブラヒム イラク サナイ ベ ティカレット アノニム シルケティ | オルメサルタン製剤処方 |
| EP2429402A4 (en) * | 2009-05-15 | 2017-03-15 | Glaxosmithkline LLC | Using thermal imaging for control of a manufacturing process |
| HUP1000325A2 (en) * | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
| AU2013235491A1 (en) * | 2012-03-22 | 2014-09-11 | Nanotherapeutics, Inc. | Compositions and methods for oral delivery of encapsulated diethylenetriaminepentaacetate particles |
| KR20150034209A (ko) | 2012-06-26 | 2015-04-02 | 델 마 파마슈티컬스 인코포레이티드 | 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법 |
| AP2015008919A0 (en) | 2013-06-20 | 2015-12-31 | Glenmark Pharmaceuticals Sa | Nanoparticulate formulation comprising a trpa1 antagonist |
| EP3024456A4 (en) | 2013-07-26 | 2017-04-12 | Update Pharma Inc. | Combinatorial methods to improve the therapeutic benefit of bisantrene |
| CN104367551B (zh) * | 2013-08-15 | 2017-06-13 | 上海星泰医药科技有限公司 | 一种阿瑞匹坦复合物及其制备方法 |
| WO2015054429A1 (en) | 2013-10-08 | 2015-04-16 | Innopharma, Inc | Aprepitant oral liquid formulations |
| EP2893919B1 (en) | 2014-01-09 | 2017-07-12 | Sanofi | Formulation of aprepitant with enhanced solubility |
| DE102014004512A1 (de) * | 2014-03-28 | 2015-10-01 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts Bereich Universitätsmedizin | Anorganisch-organische Hybridverbindung |
| HUE044602T2 (hu) | 2014-08-01 | 2019-11-28 | Glenmark Pharmaceuticals Sa | Nanorészecskés készítmény, amely egy MPGES-1 inhibitorot tartalmaz |
| KR101492572B1 (ko) | 2015-01-14 | 2015-02-11 | 주식회사 대웅제약 | 신규 약학 조성물 |
| KR20180082457A (ko) | 2015-10-16 | 2018-07-18 | 마리누스 파마슈티컬스 인코포레이티드 | 나노입자들을 포함하는 주사용 뉴로스테로이드 제제들 |
| GR1009002B (el) * | 2016-03-22 | 2017-03-31 | Φαρματεν Ανωνυμος Βιομηχανικη Και Εμπορικη Εταιρεια Φαρμακευτικων Ιατρικων Και Καλλυντικων Προϊοντων | Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| EP3481387A4 (en) | 2016-08-11 | 2020-04-08 | Ovid Therapeutics Inc | METHODS AND COMPOSITIONS FOR THE TREATMENT OF EPLEPTIC DISORDERS |
| US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
| GR1009209B (el) * | 2016-11-17 | 2018-02-05 | Φαρματεν Αβεε | Φαρμακευτικο σκευασμα περιεχον εναν αντιεμετικο παραγοντα και μεθοδος για την παρασκευη αυτου |
| CN106377517A (zh) * | 2016-11-25 | 2017-02-08 | 遵义医学院 | 银杏内酯‑pvp纳米粒及其制备方法 |
| CN107260705A (zh) * | 2017-06-08 | 2017-10-20 | 武汉励合生物医药科技有限公司 | 一种阿瑞匹坦纳米胶囊的制备方法 |
| WO2019022784A1 (en) | 2017-07-24 | 2019-01-31 | Acryspharm Llc | PHARMACEUTICAL COMPOSITIONS WITH HIGH MEDICATION CHARGE |
| JP2019073445A (ja) * | 2017-10-12 | 2019-05-16 | 日本化薬株式会社 | アプレピタントを有効成分とする医薬組成物 |
| CN108066745A (zh) * | 2017-12-26 | 2018-05-25 | 兆科药业（广州）有限公司 | 一种环孢素眼凝胶的处理工艺 |
| US20210213024A1 (en) | 2018-02-20 | 2021-07-15 | Ftf Pharma Private Ltd | Liquid compositions of aprepitant |
| EP3773559A4 (en) * | 2018-03-28 | 2021-12-22 | The Regents of The University of Colorado, A Body Corporate | TREATMENT AND PREVENTION OF INFECTION WITH THE HERPES ALPHA VIRUS |
| US11266662B2 (en) | 2018-12-07 | 2022-03-08 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of postpartum depression |
| CN110478316A (zh) * | 2019-02-27 | 2019-11-22 | 江西中医药大学 | 一种阿瑞吡坦纳米结晶混悬剂及其制备方法和应用 |
| WO2021026124A1 (en) | 2019-08-05 | 2021-02-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treatment of status epilepticus |
| KR20220134529A (ko) | 2019-12-06 | 2022-10-05 | 마리누스 파마슈티컬스 인코포레이티드 | 복합 결절성 경화증의 치료에 사용하기 위한 가낙솔론 |
| EP3915546A1 (de) | 2020-05-25 | 2021-12-01 | Leon-Nanodrugs GmbH | Verwendung von säure als lösungsmittel für präzipitationen |
| CN116077462B (zh) * | 2022-12-01 | 2025-05-16 | 北京诺康达医药科技股份有限公司 | 阿瑞匹坦微丸及其制备方法和包含它的制剂 |
| WO2025085662A1 (en) | 2023-10-17 | 2025-04-24 | Vanderbilt University | Compounds for tocolytic use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5096742A (en) | 1990-01-09 | 1992-03-17 | Hoechst Celanese Corporation | High temperature, high humidity stabilization process for optical information storage media containing polycarbonate substrates |
| US5552160A (en) * | 1991-01-25 | 1996-09-03 | Nanosystems L.L.C. | Surface modified NSAID nanoparticles |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5399363A (en) * | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US6048859A (en) * | 1992-06-29 | 2000-04-11 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| US5591456A (en) * | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
| US5573783A (en) * | 1995-02-13 | 1996-11-12 | Nano Systems L.L.C. | Redispersible nanoparticulate film matrices with protective overcoats |
| US5718919A (en) * | 1995-02-24 | 1998-02-17 | Nanosystems L.L.C. | Nanoparticles containing the R(-)enantiomer of ibuprofen |
| CA2255651A1 (en) * | 1996-06-26 | 1997-12-31 | Warner-Lambert Company | Use of a tachykinin antagonist for the manufacture of a medicament for the treatment of emesis |
| WO1998035666A1 (en) * | 1997-02-13 | 1998-08-20 | Nanosystems Llc | Formulations of nanoparticle naproxen tablets |
| US6045829A (en) * | 1997-02-13 | 2000-04-04 | Elan Pharma International Limited | Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| ZA985765B (en) † | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| GB9813025D0 (en) | 1998-06-16 | 1998-08-12 | Merck Sharp & Dohme | Chemical synthesis |
| ATE238044T1 (de) † | 1998-08-25 | 2003-05-15 | Novartis Pharma Gmbh | Verwendung von substanz p antagonisten zur behandlung des chronischen ermüdungssyndroms und/oder der fibromyalgie |
| US6165506A (en) * | 1998-09-04 | 2000-12-26 | Elan Pharma International Ltd. | Solid dose form of nanoparticulate naproxen |
| US5997905A (en) | 1998-09-04 | 1999-12-07 | Mcneil-Ppc | Preparation of pharmaceutically active particles |
| US6375986B1 (en) * | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
| US6267989B1 (en) † | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
| AU5329800A (en) | 1999-06-11 | 2001-01-02 | Merck & Co., Inc. | Process for the synthesis of 1-(3,5-bis(trifluoromethyl)-phenyl)ethan-1-one |
| US6255545B1 (en) | 1999-06-11 | 2001-07-03 | Merck & Co., Inc. | Process for the synthesis of 3,5-bis(trifluoromethyl)-bromobenzene |
| US20070179367A1 (en) * | 2000-05-02 | 2007-08-02 | Ruchti Timothy L | Method and Apparatus for Noninvasively Estimating a Property of an Animal Body Analyte from Spectral Data |
| US7801591B1 (en) * | 2000-05-30 | 2010-09-21 | Vladimir Shusterman | Digital healthcare information management |
| AU2001266690A1 (en) | 2000-06-08 | 2001-12-17 | Merck And Co., Inc. | Process for the synthesis of (2r, 2-alpha-r)-4-benzyl-2-(1-(3,5-bis(trifluoromethyl)phenyl) ethoxy)-1,4-oxazin-3-one |
| US8060173B2 (en) * | 2003-08-01 | 2011-11-15 | Dexcom, Inc. | System and methods for processing analyte sensor data |
-
2002
- 2002-09-12 UA UA20040705610A patent/UA76810C2/uk unknown
- 2002-12-03 JO JOP/2002/0126A patent/JO3060B1/ar active
- 2002-12-04 MY MYPI20024570A patent/MY155911A/en unknown
- 2002-12-05 TW TW091135282A patent/TWI249403B/zh not_active IP Right Cessation
- 2002-12-05 AR ARP020104720A patent/AR037713A1/es not_active Application Discontinuation
- 2002-12-05 PE PE2002001173A patent/PE20030641A1/es not_active Application Discontinuation
- 2002-12-09 ME MEP-2008-684A patent/ME00450B/me unknown
- 2002-12-09 SI SI200230707T patent/SI1455756T2/sl unknown
- 2002-12-09 PL PL369887A patent/PL211243B6/pl unknown
- 2002-12-09 EA EA200400794A patent/EA007332B1/ru not_active IP Right Cessation
- 2002-12-09 MX MXPA04005563A patent/MXPA04005563A/es active IP Right Grant
- 2002-12-09 CA CA002469315A patent/CA2469315C/en not_active Expired - Fee Related
- 2002-12-09 CN CNB028278143A patent/CN100352443C/zh not_active Expired - Lifetime
- 2002-12-09 BR BRPI0214786A patent/BRPI0214786B8/pt not_active IP Right Cessation
- 2002-12-09 PT PT02796109T patent/PT1455756E/pt unknown
- 2002-12-09 ES ES02796109.3T patent/ES2307820T5/es not_active Expired - Lifetime
- 2002-12-09 IL IL16229602A patent/IL162296A0/xx unknown
- 2002-12-09 HU HU0402596A patent/HU230736B1/hu unknown
- 2002-12-09 DE DE60227556T patent/DE60227556D1/de not_active Expired - Lifetime
- 2002-12-09 US US10/317,948 patent/US8258132B2/en active Active
- 2002-12-09 KR KR10-2004-7008970A patent/KR20040063991A/ko not_active Ceased
- 2002-12-09 RS YU50404A patent/RS52280B/en unknown
- 2002-12-09 GE GE5622A patent/GEP20063875B/en unknown
- 2002-12-09 HR HRP20040532AA patent/HRP20040532B1/xx not_active IP Right Cessation
- 2002-12-09 WO PCT/US2002/041655 patent/WO2003049718A1/en active Application Filing
- 2002-12-09 AU AU2002360824A patent/AU2002360824B8/en not_active Expired
- 2002-12-09 NZ NZ534009A patent/NZ534009A/xx not_active IP Right Cessation
- 2002-12-09 JP JP2003550767A patent/JP4532114B2/ja not_active Expired - Lifetime
- 2002-12-09 AT AT02796109T patent/ATE400254T1/de active
- 2002-12-09 EP EP02796109.3A patent/EP1455756B2/en not_active Expired - Lifetime
- 2002-12-09 DK DK02796109.3T patent/DK1455756T4/en active
- 2002-12-10 DO DO2002000542A patent/DOP2002000542A/es unknown
-
2004
- 2004-05-21 IS IS7276A patent/IS2991B/is unknown
- 2004-05-24 ZA ZA2004/04012A patent/ZA200404012B/en unknown
- 2004-06-01 IL IL162296A patent/IL162296A/en active IP Right Grant
- 2004-06-08 EC EC2004005144A patent/ECSP045144A/es unknown
- 2004-06-09 CO CO04054198A patent/CO5590887A2/es not_active Application Discontinuation
- 2004-07-09 NO NO20042905A patent/NO336943B1/no not_active IP Right Cessation
-
2008
- 2008-09-17 CY CY20081101013T patent/CY1108354T1/el unknown
-
2009
- 2009-10-20 IL IL201658A patent/IL201658A0/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20030641A1 (es) | Composicion nanoparticulada de 2-(r)-(1-(r)-(3,5-bis(trifluorometil)fenil)etoxi)-3-(s)-(4-fluoro)fenil-4-(3-(5-oxo-1h,4h-1,2,4-triazolo)metil morfolina) | |
| RU2319701C2 (ru) | ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I | |
| PE20091042A1 (es) | Ligandos de oxadiazol del receptor metabotropico del glutamato y su uso como potenciadores - 841 | |
| MX2022007105A (es) | Formas solidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-am ina de acido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1, 3] dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il) metil)-1h- benzo[d]imidazol-6-carboxilico. | |
| JP2009527496A5 (es) | ||
| NZ724602A (en) | Ror-gamma modulators and uses thereof | |
| RU2006122599A (ru) | Способ изготовления твердого, орально применяемого фармацевтического состава | |
| PE20080195A1 (es) | Formas cristalinas de un compuesto de dimetilfenilo | |
| JP2010513319A5 (es) | ||
| JP2005504783A5 (es) | ||
| PE20001583A1 (es) | Derivados de la 1-arenosulfonil-2-arilo-pirrolidina y de la piperidina | |
| PE20001084A1 (es) | Agentes farmaceuticos para el tratamiento de la enfermedad de parkinson, adhd y microadenomas | |
| DE60313296D1 (de) | Pharmazeutische darreichungsformen, welche einen tablettenkern mit einer bruchfestigkeit unter 38n/qcm und einen überzug zum schutz des weichen kerns enthalten | |
| CO5200757A1 (es) | Derivados de 4-indol benzamidas con actividad contra la osteoporosis, sus sales farmaceuticamente aceptables y composiciones farmaceuticas que los contienen | |
| IS2617B (is) | Fjölbrigðaform af kínínhröðunar mótlyfinu 2-(R)-(1-(R)-(3,5-bis(tríflúormetýl)fenýl)etoxý)-3-(S)-(4-flúor)fenýl-4-(3-(5-oxó-1H,4H-1,2,4-tríasóló)metýlmorfólíni | |
| US20060019970A1 (en) | Methods and compositions for the treatment of neuroleptic and related disorders using ziprasidone metabolites | |
| PE20011004A1 (es) | Composicion de liberacion controlada de un inhibidor de fosfodiesterasa 4 | |
| BR0309277A (pt) | Processo para preparação de um composto | |
| BR9914736A (pt) | Compostos de 3-(fenil substituìdo)-5-tienil-1,2,4-triazol com atividade contra mosca branca | |
| WO2005092307A3 (en) | Pharmaceutical dosage forms and compositions of 5-ht1a receptor antagonists | |
| PE20001596A1 (es) | Derivados de morfolina | |
| PE20060533A1 (es) | Derivados de dicetopiperazina como antagonistas del receptor de oxitocina | |
| WO2007030589A3 (en) | Pharmaceutical dosage forms and compositions comprising lecoztan | |
| AR045362A1 (es) | Forma cristalina estable de mesilato de bifeprunox (monometansulfonato de 7-[4-([1,1- bifenil] -3- ilmetil) -1- piperazinil] - 2-(3h) -benzoxazolona | |
| US7030142B1 (en) | Methods for the treatment of neuroleptic and related disorders using ziprasidone metabolites |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |